Candid with the CEO

Oncolytic Viruses

Manufacturing Oncolytic Viruses: Where Complexity Demands Experience

Mathias Kahl

IDT Biologika

MRD

Measurable Residual Disease Moves Deeper Into Hematologic Cancer Development

Pharma's Almanac

Biologics Platform

Platform-Based Drug Substance Development: Applying Prior Knowledge Across Modalities

Mathias Kahl

IDT Biologika

Development CDMO

The Case for Earlier CDMO Involvement in Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Biologics

Commercial Thinking Begins in Clinical Phases

Mathias Kahl

IDT Biologika

Lipase Risk

An Integrated Analytical Approach to Lipase Risk Management in Biologics Development

Kyeyeon Hur, Ph.D.; Jimin Kim, Ph.D.; Minjeong Lee; Soojeong Oh; Woojung Jun

Samsung Biologics

Potency Assurance

Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development

David Alvaro, Ph.D.

Pharma's Almanac

Site Network

How Regional Sites in a Global Site Network Combine Local Insight with Global Scale

Darin Brimhall, D.O., FACP

Trialmed

Clinical Diversity

Driving Diversity and Accessibility in Clinical Trials Starts at the Community Level

Melissa Choi, M.D.

Trialmed

Pathfinder

Surrogate Endpoints vs. Clinical Endpoints: Which Evidence Strategy Is Better for Drug Development?

Nice Insight

Oncology

Harnessing Macrophage Biology to Overcome Tumor Immune Evasion

Roy Maute, Ph.D.; David Alvaro, Ph.D.

Pheast Therapeutics

Pathfinder

Basket vs. Umbrella Clinical Trials: Which Precision Oncology Trial Design Is Better?

Nice Insight